Chaperoning prions: the story

unfolds by O'Connor, David & Jones, Gary
ROLE OF CHAPERONES IN PROTEIN
FOLDING
The information necessary for a protein
to fold into its native three-dimensional
form is contained within the primary
amino acid sequence of the polypeptide
chain. As the polypeptide chain emerges
from the ribosome, possibly even before
its synthesis is complete, it will begin the
transition through one, possibly more,
partially structured states before arriving
at the biologically active, pre-ordained
structure. Protein folding cannot occur
in a random, unbiased manner where all
possible combinations are explored in
order to reach the final structure; the so-
called Levinthal Paradox. Rather, each
protein species appears to have evolved a
conserved and simplified pathway of
folding [1].
Proteins are made in a sequential manner
with the production of small segments of
the protein at a time. As such, there are
many possibilities for misfolding.
Chaperone proteins (e.g. Heat Shock
Protein 70, Hsp70) bind to and sequester
hydrophobic regions from the surround-
ing environment, until the entire protein
is produced and the final functional con-
formation can be attained. Chaperones
are also important when dealing with
misfolded or aggregated proteins. They
may either catalyse the correct folding or
assist in the degradation on these pro-
teins. Table 1 summarises the major
cytosolic chaperones and co-chaperones
that exist in yeast and mammalian cells.
Subsets of these chaperones are involved
in the propagation of yeast and possibly
mammalian prions and as such are
potential drug targets.
PRIONS
The term prion was first coined by
Stanley Prusiner [2] to describe the
nature of the scrapie infectious agent. A
prion is an infectious protein. It is a
transmissible amyloid form of a cellular
protein that replicates by converting the
native protein into the same abnormal
prion form. Prions were first described
in mammals and are the causative
agents of transmissible spongiform
encephalopathies (TSEs). The involve-
ment of the prion protein, PrP, in TSEs is
unequivocal but solid proof that the
prion form of PrP is the sole causative
agent is still lacking. TSEs have been
described in a number of species such as
mink (TME), cat (FSE), elk (CWD) and
of course cattle (BSE) and humans
(CJD). The emergence of variant CJD
due to human consumption of prion-
infected beef is well documented. PrP
becomes infectious when it assumes a
different conformation PrPSc (its pro-
tease resistant form). PrPSc then induces
the same conformational change in cellu-
lar PrP. The prion protein then becomes
self-propagating and can be transmitted
from cell to cell usually in the form of
fibres that are rich in ß-sheets. Indeed,
the presence of amyloid protein aggre-
gates is characteristic of prion diseases.
PRIONS IN YEAST
Reed Wickner suggested that the strange
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Prions are infectious proteins that
are responsible for a number of
mammalian degenerative dis-
eases. The discovery of prions in
yeast has allowed detailed genet-
ic analysis to be carried out to
identify cellular factors involved
in prion propagation. It is now
clear that a complex relationship
exists between molecular chaper-
ones and prion propagation.
Prions may actually have evolved
to exploit the cell's chaperone
machinery to ensure their own
propagation.
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genetic behaviour of the Saccharomyces
cerevisiae non-mendelian elements [PSI]
and [URE3] could be explained if they
were prions of the Sup35 and Ure2 pro-
teins respectively [3]. Since this suggestion,
much work has accumulated to support
this notion. In addition to [PSI] and
[URE3] there are at least two other geneti-
cally well-characterised prion proteins and
several other potential prion candidates in
yeast [4]. All confirmed and potential
prion proteins in yeast have no known or
suspected functional relationships; the
only similarity between them is that they
appear to have the ability to behave in a
prion-like manner. For instance, the Sup35
protein is a translation termination factor
that allows efficient release of the nascent
polypeptide chain from the ribosome,
whereas the Ure2 protein is involved in nitrogen metabolism.
The nature of prions in yeast and fungi redefines the term prion
to encompass any protein with infectious capability and suggests
that prion phenomena may be widespread within biological
systems and may actually provide specific functions within the
cell.
Critical for establishment and propagation of yeast prion aggre-
gates is the prion-forming domain (PrD). Amino acid regions
rich in glutamines (Q) and asparagines (N) are present in all
confirmed or suspected yeast prions [4]. In vitro, the individual
PrDs are able to spontaneously undergo conformational
rearrangement in the absence of any other proteins or nucleic
acids, to generate highly stable amyloid fibrils that show all the
biophysical characteristics of the amyloid deposits in certain
neurodegenerative diseases. Therefore, in spite of the presence
of the protective mechanisms provided by chaperones, yeast
prion-containing cells are able to carry and efficiently propa-
gate high molecular weight aggregates that are absent from
prion-free cells. Such aggregates can be readily visualised by
fusing the respective prion protein to green fluorescent protein
(GFP) and observing the appearance of fluorescent foci.
CHAPERONES AND PRION PROPAGATION
The fact that prions exist in yeast provides an ideal environment
for detailed genetic analysis of factors affecting amyloid forma-
tion and prion maintenance. A number of genetic analyses have
implicated molecular chaperones of playing an essential role in
yeast prion propagation. Table 1 highlights the chaperone pro-
teins and families that have been implicated in propagation of
yeast prions.
Currently of utmost importance in yeast prion propagation is
Hsp104. The Hsp104 protein is an ATPase that is essential for
propagation of all the naturally occurring yeast prions identi-
fied so far. Hsp104 is a member of the E. coli Hsp100/ClpB fam-
ily and unlike other chaperones functions to disaggregate previ-
ously aggregated proteins. Deletion of HSP104 renders yeast
cells hypersensitive to heat stress due to their inability to resol-
ubilise aggregated proteins. Both deletion and over-expression
of HSP104 were originally shown to cure the [PSI+] prion [5]
and these results added extreme weight to the yeast prion
hypothesis. It seems that Hsp104 is necessary for the solubili-
sation of the larger prion aggregates, allowing the formation of
'seeds' or propagons, which then induce the prion conforma-
tional change in the surrounding soluble Sup35. The produc-
tion of propagons allows the efficient transmission of infec-
tious particles to daughter cells. Inhibition of Hsp104 ATPase
function, by guanidine hydro-chloride (GdnHCl) prevents the
formation of new prion propagons and leads to subsequent
prion-free (cured) descendants, after four of five generations.
Although Hsp104 is absent in mammalian systems, some pro-
teins such as p97/VCP/Cdc48p share sequence features. They
have a general chaperone-like function and their overexpres-
sion does prevent aggregation of non-transmissible polygluta-
mine aggregates but there is no evidence linking these disag-
gregation properties with any neurodegenerative disease prop-
agation. It should be noted that yeast prions exist in a cell sys-
tem that divides regularly whereas mammalian prions are
largely associated with non-dividing cells. As such, yeast
Hsp104 may have co-evolved in order to allow efficient propa-
gation of the prion in rapidly dividing cells. The lack of a
mammalian Hsp104 homologue suggests that this chaperone is
not a good candidate for development of potential drug targets
to treat prion or amyloid diseases.
  
 
 
 
 
  
 
 
 
 
  
 
  
 
 
 
 
 
 
 
  
 
 
 
  
   
 
Figure 1. Regulation of Hsp70-Ssa1 reaction cycle by co-chaperones. Substrate binding is
finely tuned by ATP hydrolysis and nucleotide exchange. Hsp70 ATPase stimulation
occurs via Hsp40, Sti1p and Cns1p. Nucleotide exchange is facilitated by Fes1p.
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Another class of molecular chaperones
implicated in yeast prion propagation is
the cytosolic Hsp70s [6]. They exist in a
number of different variants and in dif-
ferent locations within the cell. The Ssa
(Stress seventy subfamily A) family com-
prises the main class of cytosolic Hsp70,
identified as a modulator of yeast prion
propagation. Collectively the four mem-
bers of the Hsp70- Ssa family [Table 1]
provide an essential cellular function
and are also involved in various aspects
of protein folding along with other
chape-rones and co-chaperones. Other
Hsp70 members include Ssb, Ssz and Sse
proteins [Table 1].
Insight into how Hsp70-Ssa may influ-
ence prion propagation has come from
the isolation of a mutation in the SSA1
gene (SSA1-21) that impairs [PSI+]
propagation [6]. Yet in spite of this clear
effect on [PSI+] propagation, the SSA1-
21 mutation does not affect cell growth
or Ssa1p function. The SSA1-21 muta-
tion (L483W) creates a change in the
peptide-binding domain of Ssa1p, but
mapping of this residue onto the crystal
structure of E. coli Hsp70- DnaK, fails to
give any clues as to what function of
Hsp70 may be affected. Eight additional
SSA1 mutants with similar phenotypes
to SSA1-21 locate to the ATPase domain
suggesting that an alteration of the ATPase
function of Ssa1p can alter prion propaga-
tion. It is conceivable that the Ssa1-21 pro-
tein has its effects by altering the commu-
nication between the ATPase and peptide-
binding domains of the chaperone.
The location of second-site suppressors of
the SSA1-21 mutation in the ATPase and
C-terminal domains implicate Hsp40 and
tetratricopeptide repeat (TPR) co-chaper-
ones in aiding Ssa1-21p impairing [PSI+]
propagation whereas those within the
peptide-binding domain are located in
residues involved in regulating the sub-
strate trapping mechanism of Hsp70. That
mutations that weaken the substrate bind-
ing properties of Ssa1p can suppress the
SSA1-21 mutation
suggests that Ssa1-
21p has enhanced
substrate-binding
p r o p e r t i e s .
Therefore, by alter-
ing the finely tuned
Hsp70 peptide
binding cycle,
prion propagation
can be impaired.
Figure 1 summarises
the Hsp70- Ssa
ATPase cycle and
effects of perturba-
tion of this cycle on
yeast prion propagation.
In light of the fact that cells have evolved
protein folding quality control systems,
how prions managed to survive and repli-
cate in vivo is puzzling. Not only are they
able to replicate successfully but they are
also able to avoid the cellular machinery
for dealing with aggregates in terms of dis-
aggregating, re-folding, and ultimately
being degraded. In fact, it appears that pri-
ons may have evolved to exploit the cellu-
lar chaperone machinery to propagate
their own prion proteins.
ARE CHAPERONES GOOD TARGETS
FOR PRION THERAPEUTICS?
It is clear that in the yeast system the
ability of a prion to propagate success-
fully is dependent on a fine balance
between various chaperones species [7].
This gives rise to the concept that chap-
erones can theoretically be viewed as
being pro- or anti- prion in nature
[Figure 2]. The fact that chaperone
mutants can be isolated that alter propa-
gation of prions but do not affect essen-
tial cellular functions suggests that chap-
erones may be possible therapeutic tar-
gets. The yeast prion system has been
adapted for high-throughput screening
of chemical libraries to identify possible
prion-curing agents [8]. The usefulness
of this system has been confirmed by the
ability of drugs that are known to cure
mammalian prions in tissue culture, to
also cure yeast prions. Hence, there
appears to be a conserved mechanism in
the propagation of yeast and mam-
malian prions. A number of new drugs
(eg. 6-aminophenanthridine) have been
identified that cure yeast prions and
whose cellular target is not Hsp104 [8].
It is likely that these new drugs target
other protein chaperones and prevent
prion propagation, either by inhibition
of pro-prion chaperones or stimulation
of anti-prion chaperones [Figure 2] [M.
Blondel, G. Jones, Unpublished data].
The characterisation of how such chem-
icals cure prions will form the basis of
future therapeutic strategies for prion
diseases based on alteration of molecular
chaperone function.
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Figure 2. Once present in the cell [PSI+] or [PRION+] may have
"hijacked" the cellular chaperone machinery to ensure propaga-
tion.
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